Pharmacogenetics and adverse drug reports: Insights from a United Kingdom national pharmacovigilance database
Nine percent of all reported ADRs are associated with drugs where a genetic variant can cause heightened risk of an ADR and inform prescribing. A panel of only three pharmacogenes could potentially mitigate three in every four PGx modifiable ADRs. Based on our findings, Psychiatry may be the single highest impact specialty to pilot PGx to reduce ADRs and associated morbidity, mortality and costs.
Authors
- Damian Smedley (ORCID: https://orcid.org/0000-0002-5836-9850)
- Emma Forton Magavern (ORCID: https://orcid.org/0000-0003-0699-6411)
- Gabriel Marengo (ORCID: https://orcid.org/0009-0004-9420-8239)
- Mark J. Caulfield (ORCID: https://orcid.org/0000-0001-9295-3594)
- Julius O.B. Jacobsen (ORCID: https://orcid.org/0000-0002-3265-1591)
- Jack Thompson (ORCID: https://orcid.org/0009-0006-6480-3779)
- Maia Megase (ORCID: https://orcid.org/0009-0004-4797-9794)
Institutions
- St Thomas' Hospital (GB)
- Queen Mary University of London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- William Harvey Research Institute (GB)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1371/journal.pmed.1004565
- Citations
- 15
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 23.36
Funders
- Barts Charity
- University of Glasgow
- NIHR Barts Biomedical Research Centre, Queen Mary University of London